bioAffinity Technologies, Inc. develops and commercializes noninvasive diagnostics for lung cancer and other lung diseases. The company’s first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, and uses flow cytometry with automated AI-informed analysis to identify cell populations associated with lung malignancy.
Recurring company news centers on CyPath® Lung commercialization, physician adoption, clinical case studies, pulmonary nodule management, lung cancer risk assessment, and post-treatment surveillance. Updates also cover financial results, laboratory-services focus, medical conference and physician-education activity, and research extending the company’s flow cytometry+AI platform toward asthma and COPD diagnostics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) will present at the Cleveland Clinic’s Advances in Early Lung Cancer Detection symposium on April 27, 2023. Dr. Vivienne I. Rebel will discuss advancements in the company’s product, CyPath® Lung, a noninvasive test for early-stage lung cancer detection utilizing flow cytometry and artificial intelligence. The symposium aims to improve lung cancer diagnosis, particularly during its most treatable early stages. This marks bioAffinity's fourth invitation to present, underscoring its ongoing engagement in pioneering cancer detection technologies. CyPath® Lung demonstrates high sensitivity and specificity and is marketed through Precision Pathology Services. The company’s subsidiary, OncoSelect® Therapeutics, is also developing targeted cancer treatments.